drugset / Trial / NCT01049022

Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients

NCT01049022 ↗

Phase 1 Completed 31 enrolled Bayer
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to describe the pharmacokinetics of moxifloxacin in children to see what the best dose should be for children in the future. Pharmacokinetics is to see how the body absorbs, distributes, breaks down and gets rid of the study drug. The pharmacokinetics of certain drugs may be altered in children due to developmental differences in various organ functions responsible for drug elimination, as well as in general distribution characteristics. The safety of moxifloxacin in children with infections will also be looked at. Results from this study will be used to guide dosing strategies of the larger clinical trial planned for children

Timeline

Start
2010-05
Primary completion
2012-12
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxifloxacin Small molecule 5 mg/kg Intravenous
Subject Moxifloxacin Small molecule 6 mg/kg Intravenous
Subject Moxifloxacin Small molecule 7 mg/kg Intravenous
Subject Moxifloxacin Small molecule 8 mg/kg Intravenous
Subject Moxifloxacin Small molecule 9 mg/kg Intravenous
Subject Moxifloxacin Small molecule 10 mg/kg Intravenous

Indications